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Abstract
Immunological dysregulation is an important cause of the development of systemic lupus erythematosus (SLE). Serological evaluation has been useful in the clinical management of patients and as a prognostic indicator.
Sixteen patients who developed SLE as children were followed up for more than three years and immunological data collected. The results showed that (a) complement C3 concentration was lower in the active stage of SLE, especially during a major clinical exacerbation, but rarely preceded a major flare up. The concentration was often normal during the mildly to moderately active stage. In contrast, a low complement C4 concentration often preceded a major clinical exacerbation and could be of longer duration, sometimes persisting regardless of disease activity. (b) A T cell subset distribution study showed persistently low CD4 positive T cells in the peripheral blood of patients with SLE during the long term follow up, strongly suggesting that the intrinsic defect is mainly localised in T helper/inducer cells. These abnormal cellular defects did not tend to return to normal even in long term remission. (c) The persistently higher serum interleukin 2 and interleukin 2 receptor concentrations in SLE strongly suggested that the T cells were preactivated in vivo and that these phenomena might persist even in remission. (d) The best single parameter for predicting active SLE was anti-dsDNA. It was highly correlated with disease activity in most patients, and the asymptomatic increase of anti-dsDNA (>60 U/mi, radioimmunoassay) was often followed by a major clinical exacerbation, especially in patients with a simultaneously low complement C4 concentration, suggesting that it might be an important warning sign of a major flare up. High dose steroids are indicated in this group of patients.
Systemic lupus erythematosus (SLE) is a well known autoimmune disorder. Its pathogenesis, studied extensively, shows multiple immune dysregulation, which includes defective lymphokine production (interleukins 1 and 2)1 2 and decreased interleukin 2 responsiveness of T cells,3 defective antigen presenting cell-like macrophages and monocytes,4 increased spontaneous B cell activation and autoantibody production,5 decreased suppressor T cell function6 7 Table 2 shows that the weighted mean (SEM) serum interleukin 2 concentrations in the active (1[7) U/ml) and inactive stages (33 (5'2) U/ml) were higher than that of normal subjects (1[0 (0 5) U/ml, n=35); the weighted mean serum interleukin 2 receptor concentrations in both active (371 (77) U/ml) and inactive (558 (47) U/ml) disease were also higher than that of nornmal subjects (300 (89) U/ml, n=23). There was no difference, however, in serum interleukin 2 concentrations between the groups with active and inactive disease. In contrast with the serum data, no interleukin 2 was detected in culture supernatants from patients with active or inactive disease (<0 05 U/ml), whereas a small amount of interleukin 2 was detected in normal subjects (2-0 (0-5) U/ml). Figure 2 shows the changes ofserum interleukin 2 concentration in eight patients with SLE. There were marked individual variations, and some patients had a persistently high serum interleukin 2 concentration even after long term clinical remission.
antibody) were analysed further to evaluate their sensitivity, specificity, and predictive value for SLE disease activity. The result (data not shown) showed that anti-dsDNA (330 U/ml) was the most sensitive and most useful parameter for detecting active SLE (LACC ¢2); a low C3 concentration (-600 mg/I) was the least sensitive marker for active SLE, but it showed the highest specificity. An attempt was made to define the level of anti-dsDNA showing the highest predictive value, sensitivity, and specificity for active SLE. It was found that although a cut off point of :60 U/ml gave the highest specificity and predictive value for active SLE, the sensitivity was too low (0 48). If the cut off point was set at ¢30 U/ml, however, the sensitivity was increased significantly, and the predictive value and specificity were still acceptable. Thus an anti-dsDNA value of 330 U/ml was most suitable for managing SLE. Normal (n=30) 69-0 (7-7) 41-0 (6 0) 24-0 (6-1) *Active=lupus activity criteria count (LACC) ¢2; inactive=LACC <2. tA=prednisolone <10 mg/day; B=prednisolone l10 mg/day. The numbers of CD4 cells both in patients with active and inactive disease were lower than those of normal controls, whereas the numbers of CD8 cells were higher than in normal subjects. LACC (n=25, t=4-6,  p<00001 ). Both the serum interleukin 2 and C3 concentrations had a negative correlation with the LACC (p<0-02 and p<0 003 respectively). Antinuclear antibody and serum interleukin 2 receptor showed the least correlation with SLE disease activity during the long term follow up. There was no correlation between serum interleukin 2 The decreased in vitro interleukin 2 production in patients with SLE might be due to in vivo activation and thus exhaustion of T or B cells, or both. 35 We found that anti-dsDNA is the most useful parameter for the management of patients with SLE, in agreement with other reports.'0 11 43 but there are exceptions. For example, central nervous system lupus and certain haematological manifestations of SLE might have normal antidsDNA during clinical major flare ups, and some patients might have raised anti-dsDNA for months to a year but remain free from symptoms. Although during our study at least 10 patients continued to have a moderately raised anti-dsDNA level (>60 U/ml) while remaining asymptomatic or with only minimal symptoms, like mild malar rash, mild proteinuria, or haematuria, it should be noted that most of the major clinical flare ups occurred in patients with persistently high anti-dsDNA (¢s60 U/ml) who continued to take an insufficient dose of steroid (fig 3, table 5 ). Thus patients with SLE who have few or no symptoms may still have a major clinical flare up if the antidsDNA level is already moderately raised and no attempt is made to increase the drug dose. We thus recommend that all patients with SLE should have their serum anti-dsDNA and C4 concentrations determined every one to three months. Drugs should be adjusted if antidsDNA is higher than 60 U/ml, especially when serum C4 concentration is simultaneously low; management of disease in this situation is still controversial. '3 44 Finally, as low platelet count with frank bleeding tendency is often found in patients with SLE who have no clinical and serological abnormalities, but who respond to steroid treatment, we recommend that thrombocyte count should be included as one of the lupus activity criteria. 
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